Adial Pharmaceuticals Inc (ADIL) Directors and Executive Officers

Officers & Directors

Joseph M. Truluck
Chief Financial Officer
Principal Financial and Accounting Officer

Cary Claiborne
Chief Executive Officer and President
Principal Executive Officer

James W. Newman, Jr.
Member of the Board of Directors

J. Kermit Anderson
Member of the Board of Directors

Robertson H. Gilliland
Member of the Board of Directors

Kevin Schuyler
Chairman of the Board of Directors
CFA

Tony Goodman
Member of the Board of Directors ,

Adial Pharmaceuticals Inc currently has 6 employees.

News about Adial Pharmaceuticals Inc Key Personnel

Adial Pharmaceuticals on the Horizon of Change: Financial Challenges and Breakthroughs in Alcohol Use Disorder Treatment,

Overview of Financial PerformanceAdial Pharmaceuticals, Inc. (NASDAQ: ADIL), a pioneering biopharmaceutical firm based in Glen Allen, Virginia, recently published its financial results for the third quarter of 2024 and provided a comprehensive business update. The company operates in the healthcare sector, focusing on the development of therapies aimed at treating and preventing addiction and related disorders.During a one-year frame leading up to the second quarter of 2024, Adial recorded a cumulative net loss of $9 million. This financial strain has translated into a concerning negative return on investment (ROI) of -230.01%. Notably, within the healthcare industry, there were 503 other companies that dem...

“Adial Pharmaceuticals Pioneers New Pathways for Alcohol Use Disorder Treatment in Light of Evolving Recovery Definitions,

Advancements in Alcohol Use Disorder Treatment: Adial Pharmaceuticals and the Evolving Landscape of Recovery DefinedIn a pivotal moment for the treatment of Alcohol Use Disorder (AUD), Adial Pharmaceuticals is at the forefront of innovation, aligning its research efforts with the National Institute on Alcohol Abuse and Alcoholism s (NIAAA) newly defined parameters for recovery. As the NIAAA shifts its focus to include non-abstinence solutions, Adial s investigational drug, AD04, stands as a beacon of hope for millions struggling with alcohol dependence. The company s recent developments not only validate the market potential for its pioneering therapy but also highlight a significant evolution in the underst...